Journal info
|
||||
Select Journal
Journals
Bratislava Medical Journal 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 Endocrine Regulations General Physiology and Biophysics Neoplasma Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Bratislava Medical Journal Vol.119, No.11, p.701–705, 2018 |
||
Title: Comparison of transfection efficiency of polymer-based and lipid-based transfection reagents | ||
Author: P. Rahimi, V. Iranpur Mobarakeh, S. Kamalzare, F. SajadianFard, R. Vahabpour, R. Zabihollahi | ||
Abstract: OBJECTIVES: In this study, the optimal dose of Lipofectamine 3000 and Turbofect to transfect adherent cell lines such as CHO-K1 and HEK293 cells in comparison with non-adherent H9T-cells with pEGFP-N1 and pCDH was identified. BACKGROUND: Lipofectamine 3000 is a new transfection reagent which is claimed to be more efficient than other transfection reagents like Turbofect. Transfection efficiency could be affected by the nature of target cell line and vector. METHODS: Transfection efficiency and cytotoxicity of each reagent was identified by using flow cytometry and XTT assay, respectively. RESULTS: Lipofectamine 3000 was more efficient in transfecting pCDH, while Turbofect was more efficient in separate transfection of CHO-K1 and HEK293 with pEGFP-N1. Lipofectamine 3000 could be cytotoxic in transfecting H9T-cells with pCDH. Also, H9T-cells were not sufficiently transfected with each plasmid vector by using each Lipofectamine 3000 and Turbofect. Turbofect had less cytotoxicity effect on all three cell lines than Lipofectamine 3000.Transfection of suspended cells like H9T-cells by using Lipofectamine 3000 and Turbofect would not result in sufficient transfection. CONCLUSION: Lipofectamine 3000 is the best choice for transfection of CHO-K1 and HEK293 with pCDH while Turbofect is preferably used in transfecting these cell lines with pEGFP-N1 (Tab. 1, Fig. 2, Ref. 26). |
||
Keywords: cell transfection, pCDH, pEGFP-N1, Lipofectamine 3000, Turbofect | ||
Published online: 29-Nov-2018 | ||
Year: 2018, Volume: 119, Issue: 11 | Page From: 701, Page To: 705 | |
doi:10.4149/BLL_2018_125 |
||
|
download file |
|